Targeting cell spreading: a method of sensitizing metastatic tumor cells to TRAIL-induced apoptosis

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer cells, making it a promising cancer therapy.
• TRAIL resistance in many cancer cell lines limits its therapeutic efficacy.
• TRAIL plays a role in clearing tumor cells from the liver.

Purpose of the Study:

• To investigate whether interfering with cell attachment and spreading can sensitize cancer cells to TRAIL-induced apoptosis.
• To identify specific molecular targets within the integrin signaling pathway and cytoskeleton that mediate TRAIL sensitivity.

Main Methods:

• Utilized siRNA and inhibitors to target integrin signaling pathway components (β-integrins, talin, Src) and downstream survival pathways (PI3K, MAPK).
• Employed transcription factor depletion (myocardin-related transcription factor) to disrupt cytoskeletal protein synthesis.
• Assessed TRAIL-induced apoptosis in MDA-MB-231 breast cancer and 1205Lu melanoma cells.

Main Results:

• Targeting integrin pathway molecules (β-integrins, talin, Src) and survival pathways (PI3K, MAPK) sensitized both breast and melanoma cancer cells to TRAIL.
• Disrupting the cytoskeleton via transcription factor depletion also sensitized MDA-MB-231 cells to TRAIL.
• TRAIL sensitization correlated with enhanced activation of the intrinsic apoptosis pathway.

Conclusions:

• Modulating cell attachment and spreading can overcome TRAIL resistance in cancer cells.
• Targeting the integrin signaling pathway and cytoskeleton represents a viable strategy to enhance TRAIL therapy effectiveness.
• This approach holds potential for sensitizing disseminated tumor cells to TRAIL therapies in vivo.